Retinopathy of prematurity in very low birth weight infants and the potential protective role of indomethacin

Ophthalmic Surgery Lasers and Imaging

Volumn 41, Issue 1, 2010, Pages 41-47

  Goldman, Ran D ^a   Spierer, Abraham ^a   Zhurkovsky, Alexander ^b   Kwint, Jacob ^b   Schwarcz, Monica ^c   Ben Simon, Guy J ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; SURFACTANT;

APGAR SCORE; ARTICLE; FEMALE; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; RISK FACTOR; VERY LOW BIRTH WEIGHT;

CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 76149123559     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20091230-08     Document Type: Article

References (45)

1. Gibson D, Sheps SB, Uh SH, Schecter MT, McCormick AQ. Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics. 1990;86:405-412.
2. Purohit D, Ellison RC, Zieler S, Miettinen OS, Nadas AS. Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants. Pediatrics. 1985;76:339-344.
3. Lucey J, Dangman B. A re-examination of the role of oxygen in retrolental fibroplasia. Pediatrics. 1984;73:82-96.
4. Phelps D. Retinopathy of prematurity: an estimate of vision loss in the United States - 1979. Pediatrics. 1981;67:924-925.
5. Valentine PH, Jackson JC, Kalina RE, Woodrum DE. Increased incidence of low birth weight infants: impact on the incidence of retinopathy of prematurity. Pediatrics. 1989;84:442-445.
6. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity: II. The classification of retinal detachment. Arch Ophthalmol. 1987;105:906-912. Erratum in: Arch Ophthalmol. 1987;105:1498.
7. Fowlie P. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2000;2:CD000174.
8. Gallo J, Jacobson L, Broberger U. Perinatal factors associated with retinopathy of prematurity. Acta Paediatr. 1993;82:829-834.
9. Procianoy R, Garcia-Prats JA, Hittner HM, Adams JM, Rudolph AJ. Use of indomethacin and its relationship to retinopathy of prematurity in very low birthweight infants. Arch Dis Child. 1980;55:362-364.
10. Yeh T, Raval, D, Pyati S, et al. Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins. 1983;25:285-291.
11. Bolling J, Feman SS, Mellander M, Cotton R. The influence of indomethacin on retinopathy of prematurity. Am J Ophthalmol. 1983;96:254-255.
12. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001;344:1966-1972.
13. Darlow B, Horwood, LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol. 1992;6:62-80.
14. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-1134.
15. Gibson D, Sheps SB, Schechter MT, Wiggins S, McCormick AQ. Retinopathy of prematurity: a new epidemic? Pediatrics. 1989;83:486-492.
16. Ben Sira I, Nissenkorn, I, Kremer I. Retinopathy of prematurity. Surv Ophthalmol. 1988;33:1-16.
17. Arroe M, Peitersen B. Retinopathy of prematurity: review of a seven-year period in a Danish neonatal intensive care unit. Acta Paediatr. 1994;83:501-505.
18. Schaffer D, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1993;100:230-237.
19. Avery GB, Glass P. Retinopathy of prematurity: what causes it? Clin Perinatol. 1988;15:917-928.
20. Bossi E, Keener F, Flury B, Zulauf M. Retinopathy of prematurity: a risk factors analysis with univariate and multivariate statistics. Helv Paediatr Acta. 1984;39:307-317.
21. Brown D, Milley JR, Ripepi UJ, Biglan AW. Retinopathy of prematurity: risk factors in a five-year-old cohort of critically ill premature neonates. Am J Dis Child. 1987;141:154-160.
22. Clark C, Gibbs JA, Maniello R, Outerbridge EW, Aranda JW. Blood transfusion: a possible risk factor in retrolental fibroplasia. Acta Paediatr Scand. 1981;70:537-539.
23. Darlow B. Incidence of retinopathy of prematurity in New Zealand. Arch Dis Child. 1988;63:1083-1086.
24. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326:1050-1054.
25. Glass P, Avery GB, Subramanian KN, Keys MP, Sostek AM, Friendly DS. Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity. N Engl J Med. 1985;313:401-404.
26. Gunn TR, Easdown J, Outerbridge EW, Aranda JV. Risk factors in retrolental fibroplasia. Pediatrics. 1980;65:1096-1100.
27. Johnson L, Quinn GE, Abbasi S, Gerdes J, Bowen FW, Bhutani V. Severe retinopathy of prematurity in infants with birth weights less than 1250 grams: incidence and outcome of treatment with pharmacologic serum levels of vitamin E in addition to cryotherapy from 1985 to 1991. J Pediatr. 1995;127:632-639.
28. Keith C, Doyle LW. Retinopathy of prematurity in extremely low birth weight infants. Pediatrics. 1995;95:42-45.
29. Kinsey V, Amold HJ, Kalina RE, et al. PaO2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics. 1977;60:655-658.
30. Prendiville A, Schulenburg WE. Clinical factors associated with retinopathy of prematurity. Arch Dis Child. 1988;63:522-527.
31. Procianoy R, Garcia-Prats JA, Hittner HM, Adams JM, Rudolph AJ. An association between retinopathy of prematurity and ventricular hemorrhage in very low birth weight infants. Acta Paediatr Scand. 1981;70:473-477.
32. Sacks LM, Schaffer DB, Anday EK, Peckham GJ, Delivoria-Papadopoulos M. Retrolental fibroplasia and blood transfusion in very low-birth weight infants. Pediatrics. 1981;68:770-774.
33. Shohat M, Reisner SH, Krikler R, Nissenkron I, Yassur Y, Ben-Sira I. Retinopathy of prematurity: incidence and risk factors. Pediatrics. 1983;72:159-163.
34. Todd DA, Kennedy J, Roberts S, Watts J, Psaila K, John E. Retinopathy of prematurity in infants less than 29 weeks' gestation at birth. Aust N Z J Ophthalmol. 1994;22:19-23.
35. Charles JB, Ganthier R Jr, Appiah AP. Incidence and characteristics of retinopathy of prematurity in a low-income inner-city population. Ophthalmology. 1991;98:14-17.
36. Repka MX, Hardy RJ, Phelps DL, Summer CG. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol. 1993;111:618-620.
37. Batton D, Roberts C, Trese M, Maisels MJ. Severe retinopathy of prematurity and steroid exposure. Pediatrics. 1992;90:534-536.
38. The Italian ROP Study Group. Italian multicentre study on retinopathy of prematurity. Eur J Pediatr. 1997;156:939-943.
39. Kurumbail R, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644-648.
40. Green K, Cheeks L, Luxenberg MN. Topical indomethacin and prostaglandins in normal and aphakic rabbit eyes. Curr Eye Res. 1988;7:1105-1111.
41. Chemtob S, Roy MS, Abran D, Fernandez H, Varma DR. Prevention of postasphyxial increase in lipid peroxides and retinal function deterioration in the newborn pig by inhibition of cyclooxygenase activity and free radical generation. Pediatr Res. 1993;33:336-340.
42. Sakamoto T, Soriano D, Nassaralla J, et al. Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1995;113:222-226.
43. Stuart M, Phelps DL, Setty BN. Changes in oxygen tension and effects on cyclooxygenase metabolites: III. Decrease of retinal prostacyclin in kittens exposed to hyperoxia. Pediatrics. 1988;82:367-372.
44. Nandgaonkar B, Rothschild T, Yu K, Higgins RD. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res. 1999;46:184-188.
45. Sharma J, Barr SM, Geng Y, Yun Y, Higgins RD. Ibuprofen improves oxygen-induced retinopathy in a mouse model. Curr Eye Res. 2003;27:309-314.